A Teenager Asked for Cannabis Treatment. A New Study Says the Wait Got Worse, Not Better.

A 13-year-old boy tells his pediatrician he can’t stop using cannabis before school. The referral goes out that afternoon. What happens next, according to a decade of national data just re-surfaced by a wire story running in newspapers from New Hampshire to Colorado this week, is: he waits. Not a day or two — the study’s definition of a delay starts at several days and stretches past a month. And the data says his wait, statistically, just got longer than it would have been in 2018.

The system got better at closing this gap for eight straight years, and then, without a single policy reversal anyone has named, it started getting worse again.

The study behind the headline comes from Panagiota “Yiota” Kitsantas and Hong Xue at George Mason University’s College of Public Health, published in the American Journal of Preventive Medicine this spring and picked back up by state and local papers this week as cannabis-related youth treatment numbers get renewed attention. The researchers pulled more than 124,000 adolescent admissions — ages 12 to 17 — to publicly funded substance use treatment facilities across the country between 2012 and 2022, and tracked one specific outcome: how long it took from the moment a teenager sought cannabis use disorder treatment to the moment they were actually admitted.

The trend line is the finding. Delays declined steadily from 2012 through 2018 — the system, whatever combination of expanded Medicaid behavioral health coverage, insurance-parity enforcement, and treatment capacity was doing it, was getting adolescents into care faster. Then the curve reversed. By 2022, nearly 34% of adolescents seeking cannabis use disorder treatment experienced a delay, up sharply from the declining trend of the prior years — a reversal syndicated to statehouse papers nationwide this week precisely because so few local outlets have their own health-policy desk to have caught it first. Kitsantas didn’t hedge on what that means operationally: “There are persistent and rising barriers to timely treatment. There are variations in access speed across referral processes, suggesting system-level improvements are needed.”

Who waits longest tells you where the system is actually broken

The demographic breakdown is where this stops being an abstract wait-time statistic and starts looking like a map of where the referral pipeline leaks. Younger teens — 12 to 14 rather than 15 to 17 — faced more delays than older adolescents, the opposite of what you’d expect if urgency scaled with visible severity. Male adolescents faced more delays than female adolescents. White non-Hispanic youth faced more delays than other racial and ethnic groups, cutting against a lazy assumption that treatment-access gaps run in only one direction. And the referral source mattered enormously: teenagers referred into treatment through the healthcare system — a pediatrician, an ER visit, a primary care doctor flagging a problem — waited longer than teenagers who were self-referred or who came in through a school or the justice system.

That last finding is the one worth sitting with if you work anywhere near an adolescent-facing clinical pipeline. It suggests the handoff from “a doctor identified this problem” to “a treatment slot opened up” is where adolescent cannabis cases stall — not at the point of recognition, but at the point of transfer. A pediatrician can flag the problem in an afternoon; getting that flag to translate into an open bed or an outpatient appointment took the healthcare-referred group longer than it took a kid the juvenile justice system routed in through a completely different channel. Setting matters too: residential and outpatient placements had more delays than detox settings, which makes some intuitive sense — a teenager in acute crisis gets triaged faster than one who is stable but stuck.

What this study can’t tell you — and why that matters more than usual right now

Here’s the caveat a clinician reading this will already be forming, and it’s worth stating before anyone else does: this is descriptive, observational analysis of administrative admissions data, not a controlled study, and it cannot tell you why delays are rising, only that they are and who they land hardest on. The dataset covers publicly funded facilities specifically — the Treatment Episode Data Set architecture this kind of study typically draws from — so it says nothing directly about privately insured or private-pay adolescent treatment, where the access dynamics could look different, better or worse. The GMU release itself flags part of the 2020–2022 climb as plausibly tangled up with COVID-19 pandemic disruption and a simultaneous rise in demand, which means the rise in delays and the rise in need may be compounding each other rather than one simply causing the other. And because this is a single analysis of one data source, not a replication across independent datasets, the specific 34% figure should be read as this study’s finding in this population, not as an established national constant.

None of that softens the actual, falsifiable claim underneath the caveats: for eight years, a teenager asking for help with cannabis use disorder was getting into treatment faster than the year before. Then that stopped, and by 2022 it had reversed hard enough to erase most of the earlier gain. A 13-year-old doesn’t experience “system-level improvements are needed” as an abstraction — he experiences it as the six weeks between the day he told someone and the day someone actually saw him for it. If your program touches adolescent referrals, this is a maybe two-question exercise for your next team meeting: how long is your actual healthcare-to-admission gap right now, and would you have known it was widening before a national study told you?

Then that stopped, and by 2022 it had reversed hard enough to erase most of the earlier gain.